Arvinas (ARVN) Equity Income (2019 - 2020)

Arvinas' (ARVN) quarterly Equity Income came in at -$1.4 million in Q2 2020, down 227.27% quarter-over-quarter from $1.1 million in Q1 2020.

Arvinas (ARVN) Equity Income (2019 - 2020) Analysis & Trends

Arvinas' Equity Income history runs 2 years deep, the most recent figure standing at -$1.4 million for Q2 2020.

On a quarterly basis, Equity Income changed N/A year-over-year to -$1.4 million in Q2 2020; TTM through Jun 2020 was $49.5 million, a N/A change from a year earlier, with the FY2019 full-year figure at $49.8 million, changed N/A from the prior year.
Equity Income retreated to -$1.4 million in Q2 2020 per ARVN's latest filing, from $1.1 million in the prior quarter.
Across five years, Equity Income topped out at $99.3 million in Q4 2019 and bottomed at -$49.5 million in Q3 2019.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Equity Income (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	-
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	-
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	-
10	Arvinas	512.64 Mn	-102.26 Mn	-	-

Download Data